1. participant has clinical signs suggestive of severe illnesses with spo2≤94. 2. sign of severe pneumonia as determined by treating physician on x-ray or spo2 3. participant has ct≥25 at screening 4. participation in any other clinical study of an investigational agent treatment for sars-cov-2 infection within 30 days prior to the first imp dosing. 5. concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 prior to pcr screening. 6. participant with breakthrough sars-cov-2 infection within 2 weeks of sars-cov-2 vaccination. 7. history of severe renal disease (treatment with dialysis or phosphate binders) or clinically apparent hepatic impairment (e.g., jaundice, cholestasis, hepatic synthetic impairment, active hepatitis). 8. impaired cardiac function or clinically significant cardiac diseases as judged by the investigator. 9. history of anaphylaxis reaction to any known or unknown cause. 10. immunosuppressed persons as result of illness (e.g., hiv infection) or treatment. 11. documented history of bell's palsy. 12. history of allergic reaction to kanamycin. 13. immunosuppressive treatment within 3 months prior to the screening visit. 14. intranasal medication or nasal topical treatment at the time of screen and study. 15. assessed by the investigator to be ineligible to participate in the study.

1. participant has clinical signs suggestive of severe illnesses with spo2≤94. 2. sign of severe pneumonia as determined by treating physician on x-ray or spo2 3. participant has ct≥25 at screening 4. participation in any other clinical study of an investigational agent treatment for sars-cov-2 infection within 30 days prior to the first imp dosing. 5. concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 prior to pcr screening. 6. participant with breakthrough sars-cov-2 infection within 2 weeks of sars-cov-2 vaccination. 7. history of severe renal disease (treatment with dialysis or phosphate binders) or clinically apparent hepatic impairment (e.g., jaundice, cholestasis, hepatic synthetic impairment, active hepatitis). 8. impaired cardiac function or clinically significant cardiac diseases as judged by the investigator. 9. history of anaphylaxis reaction to any known or unknown cause. 10. immunosuppressed persons as result of illness (e.g., hiv infection) or treatment. 11. documented history of bell's palsy. 12. history of allergic reaction to kanamycin. 13. immunosuppressive treatment within 3 months prior to the screening visit. 14. intranasal medication or nasal topical treatment at the time of screen and study. 15. assessed by the investigator to be ineligible to participate in the study.

participant has clinical signs suggestive of severe illnesses with spo2≤94. sign of severe pneumonia as determined by treating physician on x-ray or spo2 participant has ct≥25 at screening participation in any other clinical study of an investigational agent treatment for sars-cov-2 infection within 30 days prior to the first imp dosing. concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 prior to pcr screening. participant with breakthrough sars-cov-2 infection within 2 weeks of sars-cov-2 vaccination. history of severe renal disease (treatment with dialysis or phosphate binders) or clinically apparent hepatic impairment (e.g., jaundice, cholestasis, hepatic synthetic impairment, active hepatitis). impaired cardiac function or clinically significant cardiac diseases as judged by the investigator. history of anaphylaxis reaction to any known or unknown cause. immunosuppressed persons as result of illness (e.g., hiv infection) or treatment. documented history of bell's palsy. history of allergic reaction to kanamycin. immunosuppressive treatment within 3 months prior to the screening visit. intranasal medication or nasal topical treatment at the time of screen and study. assessed by the investigator to be ineligible to participate in the study.

participant has clinical signs suggestive of severe illnesses with spo2≤94. sign of severe pneumonia as determined by treating physician on x-ray or spo2 participant has ct≥25 at screening participation in any other clinical study of an investigational agent treatment for sars-cov-2 infection within 30 days prior to the first imp dosing. concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 prior to pcr screening. participant with breakthrough sars-cov-2 infection within 2 weeks of sars-cov-2 vaccination. history of severe renal disease (treatment with dialysis or phosphate binders) or clinically apparent hepatic impairment (e.g., jaundice, cholestasis, hepatic synthetic impairment, active hepatitis). impaired cardiac function or clinically significant cardiac diseases as judged by the investigator. history of anaphylaxis reaction to any known or unknown cause. immunosuppressed persons as result of illness (e.g., hiv infection) or treatment. documented history of bell's palsy. history of allergic reaction to kanamycin. immunosuppressive treatment within 3 months prior to the screening visit. intranasal medication or nasal topical treatment at the time of screen and study. assessed by the investigator to be ineligible to participate in the study.